Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. - Test2 - elhamkhani - TriplyDB

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

http://www.wikidata.org/entity/Q33391880

about

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms The Hen or the Egg: Inflammatory Aspects of Murine MPN Models Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies Clinical potential of pacritinib in the treatment of myelofibrosis Targeting JAK2 in the therapy of myeloproliferative neoplasms Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors Janus kinase inhibitors in autoimmune diseases Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis Jakpot! New small molecules in autoimmune and inflammatory diseases Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Advances in the management of myelofibrosis JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?The evolving treatment paradigm in myelofibrosis Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine Signal transduction in the chronic leukemias: implications for targeted therapies Janus kinase inhibitors: jackpot or potluck?Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations Aging and adipose tissue: potential interventions for diabetes and regenerative medicine Novel therapies for myelofibrosis Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms JNK-induced apoptosis, compensatory growth, and cancer stem cells Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice c-Src binds to the cancer drug Ruxolitinib with an active conformation Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

P2860

Q21285040-BF93F8F1-53AB-4EFD-90C1-79EAC2A83AA6 Q24186554-F7FA9B2B-DFD4-42AC-93E3-51ECA2712E82 Q24201893-ABE2C2CA-6004-43ED-8715-DCDEA300D5B9 Q24617270-2144201E-7C7B-44B2-8F23-8B2A8B917FA7 Q26750696-156AA6C3-51FB-4D18-902E-92A228C8B7B0 Q26752940-A0DFC459-5A21-47FF-BF91-C593144EBE99 Q26766319-470DD075-28B2-4FAF-AF04-EA8BC16031B7 Q26770330-DABFEE2B-67E2-4948-A7AE-C29AC0AA1827 Q26777398-C64D8D6A-4378-4AFA-A335-9780185914F4 Q26778929-D26479A9-9E64-4DC7-B6C3-F14CFA1DD092 Q26778931-8F661581-E843-4E82-A2B9-307A68C93236 Q26779936-F40254EC-984C-499A-B47E-F99C0FA74911 Q26786973-70A80177-FBA9-41D8-9133-24EF9B39774F Q26796450-4A8C4D0F-0B40-4A80-B1AD-BADEA7E044AC Q26860796-FCA951CB-C108-4482-A9C9-960CADC57CB5 Q26863610-513B30AE-511C-479B-BC87-2A7EED37581C Q26865446-B687F67F-CE9F-4098-A722-5D66D71ECBE9 Q26996258-D5B52289-0069-44B7-B63B-F4DA9657B72B Q27001957-90287398-C32F-49BC-9415-EFA2387EA34D Q27002547-0FF272F9-2498-43C3-BF6D-AE30A1E276A1 Q27008072-2FE39E21-A58A-4179-8148-A55E875720B8 Q27012572-C8611AA1-7C2D-43D9-83DC-B17E438D07B3 Q27021968-39969D4B-F826-4496-83C8-2A40FE6F5496 Q27024626-54FABA29-E0E0-47B5-AE28-A5536AAFC3E1 Q27026031-67A38A70-C4AD-46F0-9FB9-ECCDD397D685 Q27027230-A7ABF1C4-3342-48A9-BC63-A311E41C2B01 Q27673465-BED29BB2-C28C-4943-858C-F29EA2D3343C Q27853179-0892508D-191E-4A86-A650-3FBB51FBFEBA Q28072745-B073EEC5-99CB-475F-B13C-A64E3B1E87BD Q28078404-46D7B5A7-94F2-426D-9580-0C28EF4CE914 Q28079178-3E88EB11-2A3F-48B3-881A-5F37970ED18F Q28081693-5E2F4453-96C1-4106-8C98-22BD4B82E296 Q28271752-812627C9-4C9B-44C1-A914-C07B8D88E021 Q28395713-33B9E652-460B-4BBA-8565-59ED09CFE296 Q28481327-B8F959A7-FF60-436A-992C-722EBDCAD31F Q28482297-68C15054-C4B1-4E4E-94A5-5F769C21B4D5 Q28483660-858B53C7-D19B-4D45-B9EC-3FC0121B8ED8 Q28542851-FC3F6BF6-F665-46BF-847A-4E2AAF7F8B0B Q28828592-44A71C71-0DC6-44CB-A423-BFFE9F485DDB Q30408290-7FE2ED2C-FAAE-4505-9813-882ADC6A41EA

P2860

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

http://www.wikidata.org/entity/Q33391880

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

@ast

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

@en

type

label

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

@ast

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

@en

prefLabel

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

@ast

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

@en

P1433

Q33391880-4522A7B7-EEC7-4FCB-9D35-A19B6108D3CE

P1476

Q33391880-84E5C790-A5FB-4292-87C7-90C2D21003B2

P2093

Q33391880-000967F3-4421-4AC5-80E0-0BE11FB413D7

Q33391880-040D3723-1377-4F3E-845A-3CD3B85F0F66

Q33391880-284A00FD-C35D-4B95-91EA-CE08246E5662

Q33391880-3D070328-B91E-4D89-B8E8-02B64CAE6A73

Q33391880-64F7F4D4-F75C-4AA4-A6E1-018CCFE969E6

Q33391880-AEEB058A-5EF5-4B21-8615-3CEF6C4A0467

Q33391880-B87CD123-4EBA-4185-AFB4-85139AD5DC6E

Q33391880-C620EC71-5E6A-44A3-9851-129085FCA0B0

Q33391880-DB45AFC6-71F3-403E-B1D7-E4AAE1272598

P2860

Q33391880-10BCA3F1-B390-45D3-BD36-8E2031B6B330

Q33391880-23BCED2C-E8A8-4171-8E96-F1A7847FB3FE

Q33391880-298A233A-3166-45A4-A2B1-751CE1D6E7CC

Q33391880-3007DD38-2103-450A-862D-6BCFB4E4EA86

Q33391880-376EEC08-70A7-4AD0-ACAF-FC1BB6657CA3

Q33391880-43A38337-126D-4273-B8EA-8A2358400820

Q33391880-48CB01C0-2BA1-4FBA-ACE0-75A731BA7E50

Q33391880-5420C2DB-38B1-4CFF-9227-BB670B3D28FA

Q33391880-6DCCBDF1-4632-47A4-8810-DB16D4275E3B

Q33391880-8C17CBB9-955C-4866-84C7-CC79F8EEDAD4

P304

Q33391880-0ADE50B0-8442-4FE0-90BE-839C1358D605

P31

Q33391880-33E7B702-9444-4BB1-A053-5B2C0B291550

P356

Q33391880-3E801F3B-8F61-46AA-9045-C0D244FA9096

P407

Q33391880-02740F46-D781-430C-A3CB-DA85C0467D80

P433

Q33391880-60A707B9-17F2-4462-A832-52C44F0433CE

P478

Q33391880-3F1509E2-BF86-4930-ACF9-202FDD09769F

P50

Q33391880-2F16772C-B017-42B3-8730-7A198BA1C247

Q33391880-ADD5F17A-E858-464D-BE24-8DDA6A1112C1

Q33391880-B841A5BC-436A-4FC2-9E4C-29D5337F2BAE

Q33391880-CD3DEEF1-B282-4873-AE3B-6218DCE00186

P577

Q33391880-2D8EAC5E-1FA9-4DF0-B16D-7575EDC67171

P698

Q33391880-FF7DDDB6-C1DA-4F7F-AC43-A5A0B963B1F0

P932

Q33391880-0FD2FC22-EB41-4001-95C7-6D9C3A8C05C2

P356

P1433

The New England Journal of Medicine

P1476

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

@en

P2093

Animesh D Pardanani

http://www.w3.org/2001/XMLSchema#string

Deborah A Thomas

http://www.w3.org/2001/XMLSchema#string

Edward C Bradley

http://www.w3.org/2001/XMLSchema#string

Jordan S Fridman

http://www.w3.org/2001/XMLSchema#string

Jorge Cortes-Franco

http://www.w3.org/2001/XMLSchema#string

Kris Vaddi

http://www.w3.org/2001/XMLSchema#string

Richard Levy

http://www.w3.org/2001/XMLSchema#string

Ruben A Mesa

http://www.w3.org/2001/XMLSchema#string

Susan Erickson-Viitanen

http://www.w3.org/2001/XMLSchema#string

P2860

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

The role of cytokines in cancer-related fatigue.

New insights into the pathogenesis and drug treatment of myelofibrosis.

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

Crossroads of cytokine signaling--the chase to stop muscle cachexia.

P304

1117-1127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1002028

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Srdan Verstovsek

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20843246

http://www.w3.org/2001/XMLSchema#string

P932

5187954

http://www.w3.org/2001/XMLSchema#string